CN107788529A - A kind of health composition of strengthen immunity containing saline cistanche and its beverage - Google Patents
A kind of health composition of strengthen immunity containing saline cistanche and its beverage Download PDFInfo
- Publication number
- CN107788529A CN107788529A CN201610785669.5A CN201610785669A CN107788529A CN 107788529 A CN107788529 A CN 107788529A CN 201610785669 A CN201610785669 A CN 201610785669A CN 107788529 A CN107788529 A CN 107788529A
- Authority
- CN
- China
- Prior art keywords
- saline cistanche
- strengthen immunity
- mouse
- american ginseng
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 230000036039 immunity Effects 0.000 title claims abstract description 56
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title claims abstract description 50
- 241000005787 Cistanche Species 0.000 title claims abstract description 47
- 239000011780 sodium chloride Substances 0.000 title claims abstract description 45
- 230000036541 health Effects 0.000 title claims abstract description 23
- 235000013361 beverage Nutrition 0.000 title claims abstract description 14
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 33
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 230000007812 deficiency Effects 0.000 claims abstract description 7
- 208000031975 Yang Deficiency Diseases 0.000 claims abstract description 4
- 241001247821 Ziziphus Species 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 235000013336 milk Nutrition 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- 238000005520 cutting process Methods 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 239000011800 void material Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000005195 poor health Effects 0.000 abstract description 2
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 75
- 230000037396 body weight Effects 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 230000000242 pagocytic effect Effects 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000003304 gavage Methods 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 108010062580 Concanavalin A Proteins 0.000 description 9
- 230000002949 hemolytic effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000005534 hematocrit Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 241000167880 Hirundinidae Species 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- YHVQIDWAIRCSOQ-UHFFFAOYSA-N 1-nitrotetrazol-2-ium chloride Chemical compound [Cl-].[O-][N+](=O)N1C=[NH+]N=N1 YHVQIDWAIRCSOQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000804765 Mus musculus Lymphotactin Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of health composition of strengthen immunity containing saline cistanche and its beverage, the raw material that said composition is matched by following weight to be made：Saline cistanche：2~4 parts；American Ginseng：1~3 part；Jujube：16~24 parts.Health composition and its beverage of the present invention are particularly suitable for deficiency of both qi and yin, kidney-yang deficiency, deficiency in both YIN and YANG and in poor health, malnutritive crowd, and the preparation method of the present invention is simple to operate, environmentally friendly, economical, efficient, nontoxic, has broad application prospects.
Description
Technical field
The invention belongs to field of food, is related to a kind of health drink of strengthen immunity containing saline cistanche and preparation method thereof.
Background technology
The traditional Chinese medical science thinks, when internal gas, blood, yin, yang lack insufficient, asthenic symptoms, i.e., common hypoimmunity disease just occurs
Easy fever etc. after shape, including repeated cold, lassitude, tired powerless, breathing shortness of breath, easy perspiration, flu.And modern doctor
Learn research and show that the disease of the mankind 99% is all relevant with immune system, so the development and exploitation of enhancing immunity of organisms product
Turn into one important problem of today's society, and lift abundance and balance that immunity seeks to ensure gas, blood, yin, yang.
In order to solve above-mentioned technical problem present in prior art, the invention provides one kind can effectively strengthen body
Immunity, safely and effectively and the health drink of strengthen immunity that has no toxic side effect and preparation method thereof.
The content of the invention
It is contemplated that a kind of health composition with strengthen immunity function of exploitation, especially by said composition system
Into health drink, can nourishing qi and blood, clearing heat and promoting fluid, kidney-replenishing helps sub-health population to improve malaise symptoms, and improves it and support
The ability of anti-disease.
The purpose of the present invention is achieved in the following ways：
A kind of health composition containing saline cistanche of strengthen immunity, the raw material system that said composition is matched by following weight
Into：Saline cistanche：2~4 parts；American Ginseng：1~3 part；Jujube：16~24 parts.
The preparation method of the health composition containing saline cistanche of above-mentioned strengthen immunity comprises the following steps：
Saline cistanche, American Ginseng, jujube are added water to cook 1-2 times, and every time plus 7-25 times is measured decocting and boil 1-3 hours；Extraction terminates
Afterwards, all filtrates are collected, lets cool, centrifuge, take supernatant, concentrate and produce.
The health composition containing saline cistanche of above-mentioned strengthen immunity prepare alleviate or improve deficiency of both qi and yin, kidney-yang deficiency,
Applied in deficiency in both YIN and YANG and weakly health food.Described health food is beverage or powdery or granular nutrient powder
Or dry food.
A kind of health drink containing saline cistanche of strengthen immunity, the raw material that the beverage is matched by following weight are made：Meat
Desert cistanche：2~4 parts；American Ginseng：1~3 part；Jujube：16~24 parts, milk powder：20~40 parts.
The preparation method of the health drink containing saline cistanche of above-mentioned strengthen immunity comprises the steps：
1. pretreatment of raw material：Saline cistanche, American Ginseng, jujube cleaning, 30-50 DEG C of low temperature drying are taken respectively, use preceding difference
Saline cistanche, American Ginseng are subjected to cutting, cutting flakiness or fritter；
2. extraction：Saline cistanche, American Ginseng, jujube are added water to cook 1-2 times in the present invention, and every time plus 7-25 times is measured decocting and boil 1-
3 hours；
3. centrifugation：After extraction terminates, all filtrates are collected, lets cool, centrifuge, take supernatant；
4. match somebody with somebody liquid：Add milk powder and beverage is made.
Compared with the prior art, the present invention has following features：
1. theory and clinical experience choosing side that the present invention raises according to Traditional Chinese Medicine dietotherapy, using pure natural Raw material processing system
Into a kind of, there is provided functional food that can effectively strengthen immunity of organisms, selected each medicine is that raw-food material or country permit in side
It is allowable in being strictly limited in certain limit on functional food raw material, dosage, so safely and effectively, long-term use has no toxic side effect,
It can be eaten for a long time.
2. saline cistanche kidney-replenishing of the present invention, benefiting essence-blood, American Ginseng boosting qi and nourishing yin, clearing heat and promoting fluid；Jujube bowl spares
QI invigorating, nourishing blood and tranquilization；The nourishing the stomach of milk tonifying lung, promote the production of body fluid, ease constipation, calm the nerves, containing abundant protein.It is prepared by above each component compatibility
Health drink into strengthen immunity has the function that to promote human lymphocyte propagation.
3. the health composition and its beverage of strengthen immunity prepared by the present invention be particularly suitable for deficiency of both qi and yin, kidney-yang deficiency,
Deficiency in both YIN and YANG and in poor health, malnutritive crowd.
3. the preparation method of the present invention, simple to operate, environmentally friendly, economical, efficient, nontoxic, have broad application prospects.
Embodiment
Make more detailed illustrate to the present invention with reference to instantiation.
Embodiment one：
First, the strengthen immunity health drink of this example production, is prepared by the raw material and auxiliary material of following parts by weight：
Saline cistanche 10g
American Ginseng 5g
Jujube 80g
Milk powder 200g
2nd, the health food of this example production, is carried out as steps described below：
1. pretreatment of raw material：Take saline cistanche, American Ginseng, jujube cleaning, low temperature (30-50 DEG C) to be dried for standby respectively, use
It is preceding that saline cistanche, American Ginseng are subjected to cutting, cutting flakiness or fritter respectively；
2. extraction：Saline cistanche, American Ginseng, jujube are added water to cook 2 times, and every time plus 13 times of amount decoctings are boiled 1 hour；
3. centrifugation：After extraction terminates, all filtrates are collected, room temperature lets cool, centrifuged, and takes supernatant；
4. match somebody with somebody liquid：Qualified milk powder will be examined to be dissolved in the supernatant in step 3, beverage is made.
Embodiment two：
First, the strengthen immunity health drink of this example production, is prepared by the raw material and auxiliary material of following parts by weight：
Saline cistanche 15g
American Ginseng 10g
Jujube 100g
Milk powder 150g
2nd, the health food of this example production, is carried out as steps described below：
1. pretreatment of raw material：Take saline cistanche, American Ginseng, jujube cleaning, low temperature (30-50 DEG C) to be dried for standby respectively, use
It is preceding that saline cistanche, American Ginseng are subjected to cutting, cutting flakiness or fritter respectively；
2. extraction：Saline cistanche, American Ginseng, jujube are added water to cook 1 time in the present invention, and every time plus 25 times of amount decoctings are boiled 3 hours；
3. centrifugation：After extraction terminates, all filtrates are collected, room temperature lets cool, centrifuged, and takes supernatant；
4. match somebody with somebody liquid：Qualified milk powder will be examined to be dissolved in the supernatant in step 3, beverage is made.
Embodiment three：
First, the strengthen immunity health drink of this example production, is prepared by the raw material and auxiliary material of following parts by weight：
Saline cistanche 20g
American Ginseng 15g
Jujube 120g
Milk powder 200g
2nd, the health food of this example production, is carried out as steps described below：
1. pretreatment of raw material：Take saline cistanche, American Ginseng, jujube cleaning, low temperature (30-50 DEG C) to be dried for standby respectively, use
It is preceding that saline cistanche, American Ginseng are subjected to cutting, cutting flakiness or fritter respectively；
2. extraction：Saline cistanche, American Ginseng, jujube are added water to cook 2 times in the present invention, and every time plus 8 times of amount decoctings are boiled 1 hour；
3. centrifugation：After extraction terminates, all filtrates are collected, room temperature lets cool, centrifuged, and takes supernatant；
4. match somebody with somebody liquid：Qualified milk powder will be examined to be dissolved in the supernatant in step 3, beverage is made.
Research and explanation to present composition pharmacodynamics：
Inventor has carried out experimental study to technical scheme provided by the invention, for proving the technique effect of the present invention,
It is following to test for further illustrating the technique effect of the present invention, but do not limit the present invention.
The present composition strengthens the Effect study of immunity of organisms
1. experiment material
1.1 animal
ICR mouse, cleaning grade, 18~21g, female, purchased from Yangzhou University's comparative medicine center, quality certification number：SCXK
(Soviet Union) 27~0001.
1.2 medicines and reagent
Sheep red blood cell (SRBC) (SRBC), physiological saline, Hank ' s liquid (pH 7.2-7.4), RPMIl640 nutrient solutions, small ox blood
Clearly, penicillin, streptomysin, concanavalin A (ConA), 1% glacial acetic acid, 1mol/L HCl solution, (96mL is different for acid isopropyl alcohol
Propyl alcohol adds 1mol/L HCl solution 4mL), MTT, PBS (pH 7.2-7.4), complement (guinea pig serum), SA buffer solutions,
Agarose, Dou Shi reagents (sodium acid carbonate 1.0g, high-potassium ferricyanide 0.2g, potassium cyanide 0.05g, adding distilled water to 1000mL),
YAC-1 cells, lithium lactate, nitro tetrazolium chloride, PMS, oxidized coenzyme I, 0.2mol/L Tris-
HCl buffer solutions (pH 8.2), 1%NP40, india ink, 0.1%Na2CO3, chicken red blood cell, methanol, Giemsa dye liquors etc..
1.3 instrument
ES-2100A electronic balances, BS223S electronic balances, 755 spectrophotometers, ELIASA, CO2gas incubator,
Low speed centrifuge, water bath with thermostatic control, microscope, inverted microscope, spiral micrometer.
Clean bench, sterile surgical instrument, micro syringe (25 μ L), cell counter, 24 holes and 96 holes are flat thin
Born of the same parents' culture plate, the U-shaped Tissue Culture Plate in 96 holes, glass dish, gauze, test tube, glass frame, 200 eye mesh screens, timer, hemochrome
Suction pipe, slide etc..
2. experimental method
2.1 packets are set with dosage
Dosage setting principle：This composition recommended dose is adult (pressing 60kg batheroom scales) daily 1.86g, equivalent to
0.031g/ days/kg body weight.Experiment sets 5 times, 10 times, 30 times of human body recommended amounts, i.e., daily 0.151g/kgBW, 0.31g/
KgBW, 0.93g/kgBW are basic, normal, high dosage group.
Blank control group：Give distilled water gavage, 0.2ml/20g body weight gavages；
Low content group：The composition of embodiment 1, this group of preparation of 0.151g/kgBW is given per 1kg body weight according to mouse, is steamed
Distilled water wiring solution-forming, 0.2ml/20g body weight gavages；
Middle content groups：The composition of embodiment 1, this group of preparation of 0.31g/kgBW is given per 1kg body weight according to mouse, is distilled
Water wiring solution-forming, 0.2ml/20g body weight gavages；
The composition of high content group embodiment 1, this group of preparation of 0.93g/kgBW is given per 1kg body weight according to mouse, is distilled
Water wiring solution-forming, 0.2mL/20g body weight gavages；
A1 groups：Misrun desert cistanche, take the parts by weight of American Ginseng 3, the parts by weight of jujube 24；Above composition is according to the side of preparation of embodiment 1
Preparation is made in method, gives this group of preparation 0.3g standard, distilled water wiring solution-forming, 0.2mL/20g bodies per 1kg body weight according to mouse
Weight gavage；
A2 groups：American Ginseng is lacked, takes the parts by weight of saline cistanche 4, the parts by weight of jujube 24；Above composition is according to the side of preparation of embodiment 1
Preparation is made in method, gives this group of preparation 0.3g standard, distilled water wiring solution-forming, 0.2mL/20g bodies per 1kg body weight according to mouse
Weight gavage；
A3 groups：Lack jujube, the parts by weight of saline cistanche 4, the parts by weight of American Ginseng 3；Above composition is according to the preparation method system of embodiment 1
Into preparation, this group of preparation 0.3g standard, distilled water wiring solution-forming are given per 1kg body weight according to mouse, 0.2mL/20g body weight fills
Stomach；
A4 groups：Containing only saline cistanche, the parts by weight of saline cistanche 4；Preparation is made according to the preparation method of embodiment 1 in above composition, presses
This group of preparation 0.3g standard, distilled water wiring solution-forming, 0.2mL/20g body weight gavages are given per 1kg body weight according to mouse；
A5 groups：Containing only American Ginseng, the parts by weight of American Ginseng 3；Preparation is made according to the preparation method of embodiment 1 in above composition, presses
This group of preparation 0.3g standard, distilled water wiring solution-forming, 0.2mL/20g body weight gavages are given per 1kg body weight according to mouse；
A6 groups：Containing only jujube, the parts by weight of jujube 24；Preparation is made according to the preparation method of embodiment 1 in above composition, according to small
Mouse gives this group of preparation 0.3g standard, distilled water wiring solution-forming, 0.2mL/20g body weight gavages per 1kg body weight；
2.2 experimental animals and administration
300 ICR mouse are divided into 3 batches, 100 every batch, every batch is randomly divided into 10 groups, every group 10.
(1) a collection of progress carbonic clearance experiment is tested；
(2) two batches are tested and carries out dirty body ratio measurement, the experiment of Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell, delayed change
State reaction experiment, half hemolytic value (HC50) measure and antibody-producting cell number measure；
(3) determination of activity of the mouse lymphocyte transformation experiment, NK cells of three batches of progress ConA inductions is tested.
Daily oral gavage gives 2.1 lower experimental group compositions once, and blank group gives distilled water, and gavage volume is
0.2ml/20gBW, continuous gavage 30 days.
2.3 Testing index
Body weight, internal organs/body weight ratio, vola pedis thickness, the competence for added value of lymphocyte, antibody-producting cell number, half are molten
Blood value (HC50), carbonic clearance index, the phagocytic rate of phagocyte and phagocytic index, NK cytoactives.
3. experimental method
The measure of 3.1 internal organs/body weight ratio
Cervical dislocation is put to death after mouse is weighed, and takes spleen and thymus gland, removes most manadesma, organ surface blood stains are blotted with filter paper,
Weigh, calculate spleen/body weight ratio and thymus gland/body weight ratio.
(vola pedis thickens method) is tested in 3.2 delayed allergies (DTH)
Sheep blood is taken, brine 3 times, every mouse is through being injected intraperitoneally 2% (v/v, with normal saline) hematocrit
SRBC (2000r/min, 10min) 0.2mL, 4d after sensitization, measure left back foot plantar thickness, and same position measurement three times, is made even
Average.Then 20% (v/v, with normal saline) hematocrit SRBC20 μ L are subcutaneously injected in measuring point, 24h is surveyed after injection
Left back foot plantar thickness is measured, DTH degree is represented with the difference of vola pedis thickness before and after attack.The difference of test sample group is notable
Higher than the difference of control group, this experimental result positive can determine that.
The mouse lymphocyte transformation experiment (mtt assay) of 3.3ConA inductions
It is sterile to take spleen, it is placed in the small plate for filling appropriate sterile Hank ' s liquid, gently spleen is ground with tweezers, list is made
Individual cell suspension.Through 200 mesh sieve net filtrations, cell suspension is made.Washed 3 times with Hank ' s liquid, centrifuge 10min (1000r/ every time
min).Then cell is suspended in 1mL complete culture solution, microscopy counts, and adjustment cell concentration is 3 × 106/mL.Again
Holes is divided to add in 24 well culture plates splenocyte suspension, per hole 1mL, a hole adds 75 μ LConA liquid (equivalent to 7.5 μ wherein
G/mL), 5%CO is put in another hole as control2, 37 DEG C of CO272h is cultivated in incubator.Culture terminates preceding 4h, is gently sucked per hole
Supernatant 0.7mL, add 0.7mL and be free of the RPMI1640 nutrient solutions of calf serum, while add the μ L/ holes of MTT (5mg/mL) 50,
Continue to cultivate 4h.After culture terminates, 1mL acid isopropyl alcohol is added per hole, piping and druming mixes, and is completely dissolved purple crystal.Then
This liquid is moved into cuvette, the colorimetric estimation on 755 spectrophotometers, wavelength 570nm.The multiplication capacity of lymphocyte is used
Add the OD value in ConA holes to subtract to be not added with the OD value in ConA holes and represent the competence for added value of lymphocyte.Test sample group
Optical density difference is significantly higher than the optical density difference of control group, can determine that this experimental result positive.
The measure (Jerne improves slide methods) of 3.4 antibody-producting cell numbers
Sheep blood is taken, brine 3 times, every mouse is through being injected intraperitoneally 2% (v/v, with normal saline) hematocrit
SRBC0.2mL.Mouse cervical dislocation after SRBC is immunized 5 days is put to death, and is taken out spleen, is gently ground spleen, cell is made and hangs
Liquid.(1000r/min) 10min is centrifuged, is washed 2 times with Hank ' s liquid, finally by cell suspension in 8mLHank ' s liquid.By agar
After sugar dissolves by heating, mix with equivalent double Hank ' s liquid, dispense small test tube, every pipe 0.5mL, then add into pipe 10% (v/v,
Prepared with SA liquid) hematocrit SRBC50 μ L, the μ L of splenocyte suspension 8, after rapid mixing, it is poured into the slide of brush agarose thin layer
On, parallel plate is done, after agar solidification, horizontal buckle of slide is placed on horse, is put into 37 DEG C of incubations in CO2gas incubator
1h, the complement (1: 8) then diluted with SA buffer solutions are added in glass frame groove, continue after incubating 1.5h, it is empty to count haemolysis
Spot number.Represented with plaque number/full spleens cell number.The plaque number of test sample group is significantly higher than the plaque number of control group, can sentence
Fixed this experimental result positive.
The measure of 3.5 half hemolytic values (HC50)
Sheep blood is taken, brine 3 times, every mouse is through being injected intraperitoneally 2% (v/v, with normal saline) hematocrit
SRBC0.2mL is immunized.After 5 days, extract eyeball and take blood to place about 1h in centrifuge tube, solidification blood and tube wall are peeled off, made
Serum fully separates out, and 2000r/min centrifugation 10min, collects serum.With SA buffer solutions by serum-dilution be 300 times, take 1mL to put
In test tube, sequentially add 10% (v/v, with SA buffers) hematocrit SRBC0.5mL, complement 1mL and (press 1: 8 with SA buffer solutions
Dilution).The another control tube for setting not increase serum (with the replacement of SA buffer solutions).Put after being incubated 15min in 37 DEG C of waters bath with thermostatic control, ice bath is whole
Only react.2000r/min centrifuges 10min, takes supernatant 1mL, adds Dou Shi reagents to 3mL.Take 10% (v/v, with SA buffer solutions simultaneously
Prepare) hematocrit SRBC0.25mL, add Dou Shi reagents to 4mL in another test tube, fully mix, place 10min after, in
540nm sentences control tube and makees blank, determines each pipe OD value respectively.
The amount of hemolysin is with half hemolytic value (HC50) represent, it is calculated as follows：
OD value × extension rate during sample half hemolytic value=sample OD value/SRBC half hemolysis
The HC of test sample group50It is significantly higher than the HC of control group50, can determine that this experimental result positive.
3.6 mouse carbonic clearances are tested
4 times of india ink (0.05mL/10g) is diluted from mouse tail vein injection by body weight, treats that prepared Chinese ink injects, counts immediately
When.2,10min, takes the μ L of blood 20, and be added into 2mL0.1%Na from angular vein clump respectively after injection prepared Chinese ink2CO3In solution.
With 755 spectrophotometers at 600nm wavelength densitometric value (OD), with Na2CO3Solution makees blank control.Mouse is put to death,
Liver and spleen is taken to weigh.The ability of mouse carbonic clearance is represented with carbonic clearance index (a), a is calculated as follows：
K=(logOD1-logOD2)/(t2-t1)
A=body weight ÷ (liver weight+spleen weight) × k1/3
The carbonic clearance index of test sample group is significantly higher than the carbonic clearance index of control group, can determine that this experimental result sun
Property.
3.7 Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell experiment (half intracorporal method)
Mouse peritoneal injection 20% (v/v, with normal saline) chicken red blood cell (2000r/min, 10min) suspension 1mL,
30min is spaced, cervical dislocation is put to death, faced upward position and be fixed on mouse plate, through abdominal cavity saline injection 2mL, rotates mouse plate
1min.Peritoneal macrophage washing lotion 1mL is taken, drips on 2 slides, is put into the enamel box for being lined with wet gauze, dislocation respectively
37 DEG C of incubators incubate 30min.Incubate complete, rinsed in physiological saline, to remove non-paster cell.Dry, with acetone:Methanol=1：
1 solution is fixed, the dyeing of Gicmsa- phosphate buffers, then is dried with distilled water rinsing.Counted under oil mirror, every counting 100 is huge
Phagocyte, phagocytic rate and phagocytic index is calculated as follows：
Number of macrophages × 100 of number of macrophages/counting of phagocytic percentage (%)=phagocytosis chicken red blood cell
The number of macrophages of the chicken red blood cell sum/counting for phagocytic index=swallowed
The phagocytic percentage drawn carries out data conversion as the following formula again,P is phagocytic percentage in formula, is used
Fractional representation.The phagocytic percentage and phagocytic index of test sample group are all remarkably higher than the phagocytic percentage of control group and phagocytosis refers to
Number, can determine that this experimental result positive.
The measure (lactate dehydrogenase L DH determination methods) of 3.8NK cytoactives
Target cell YAC-1 is carried out Secondary Culture by 24h before experiment, is washed 3 times with Hank ' s liquid using preceding, with containing 10% calf
The RPMI1640 complete culture solutions adjustment cell concentration of serum is 4 × 105/mL.Test mice cervical dislocation is put to death, sterile to take
Spleen, splenocyte suspension is made, is washed 2 times with Hank ' s liquid, centrifuge 10min (1000r/min) every time.Supernatant is abandoned by cytoplasm bullet
Rise, add 0.5mL aqua sterilisa 20s, 0.5mL2 times of Hank ' s liquid and 8mLHank ' s liquid, 1000r/ are added after splitting erythrocyte
Min, 10min are centrifuged, and are resuspended with RPMI1640 complete culture solutions of the 1mL containing 10% calf serum, microscopy counts, and uses RPMI1640
Complete culture solution adjustment cell concentration is 2 × 107/mL.It is 50: 1 to make effect target ratio.Target cell and each 100 μ L of effector cell are taken,
Add in the well culture plate of U-shaped 96；Target cell Spontaneous release hole adds target cell and each 100 μ L of nutrient solution, target cell maximum release aperture
Add target cell and each 100 μ L of 1%NP40；Above-mentioned items are all provided with three parallel holes, 37 DEG C, 5%CO24h is cultivated in incubator, will
96 orifice plates centrifuge 5min with 1500r/min, are drawn per hole in the well culture plate of 100 μ L horizontalizations bottom of supernatant 96, add LDH matrix liquids
100 μ L, 3-10min is reacted, the 1mol/L μ L terminating reactions of HCl solution 30, the light-metering at ELIASA 490nm are then added per hole
Density value (OD), calculate NK cytoactives：
NK cytoactives (%)=(reacting hole OD- Spontaneous releases hole OD)/(maximum release aperture OD- Spontaneous releases hole OD) ×
100
The NK cytoactives drawn carry out data conversion as the following formula,P is NK cytoactives in formula, and use is small
Number represents.The data obtained is measurement data, and the NK cytoactives of test sample group are significantly higher than the NK cytoactives of control group, can
Judge this experimental result positive.
3.9 data processing
Data processing is carried out with SPSS softwares.Using variance analysis, but it is neat first to carry out variance by the program of variance analysis
Property examine, variance is neat, calculate F values, F value ＜ F0.05, conclusion：No significant difference between each group mean, F values >=F0.05, P≤0.05,
Counted with the comparative approach two-by-two of mean between multiple experimental groups and a control group；To the data of abnormal or heterogeneity of variance
Appropriate variable conversion is carried out, after normal state or the neat requirement of variance is met, is counted with the data after conversion；If variable is changed
Normal state or the neat purpose of variance are still not up to afterwards, are used rank test instead and are counted.
3.10 result judgement foundation
《Health food is examined and assessment technique specification)》(2003 editions) regulations：In cellular immune function, humoral immunity work(
Energy, monocytes/macrophages function, any two aspect results of four aspects of NK cytoactives are positive, can determine that the given the test agent has
There is strengthen immunity function.Two experimental results wherein in cellular immune function assay project are the positive, or any
Two dosage group results of experiment are positive, can determine that the cellular immune function assay result positive.Humoral immune function determines project
In two experimental results be the positive, or two dosage group results of any experiment are positive, can determine that humoral immune function is surveyed
Determine the result positive.Two experimental results in monocytes/macrophages functional examination project are the positive, or two of any experiment
Dosage group result is positive, can determine that the monocytes/macrophages function result positive.More than one agent of NK cytoactive detections experiment
Amount group result is positive, can determine that the NK cytoactives result positive.
4. experimental result
(1) influence of the composition of present invention energy strengthen immunity to mouse weight, is shown in Table 1,2,3：
Influence of the composition of the present invention energy strengthen immunity of table 1 to a collection of mouse weight of experiment
Influence of the composition of the present invention energy strengthen immunity of table 2 to two batches of mouse weights of experiment
Influence of the composition of the present invention energy strengthen immunity of table 3 to three batches of mouse weights of experiment
From table 1-3, mouse during each dosage group experiment initial stage, experiment mid-term, experiment latter stage mouse weight and experiment
Body weight increase is compared with blank control group, and there are no significant for difference (P ＞ 0.05), i.e., this composition to mouse weight without bad shadow
Ring.
(2) influence of the composition of present invention energy strengthen immunity to mouse immune organ internal organs/body weight ratio, is shown in Table 4：
Influence of the composition of the present invention energy strengthen immunity of table 4 to mouse immune organ internal organs/body weight ratio
From table 4, the composition of the present invention energy strengthen immunity of orally administration mouse various dose 30 days, to mouse
Spleen/body weight ratio and thymus gland/body weight ratio do not make significant difference (P ＞ 0.05).
(3) influence of the composition of present invention energy strengthen immunity to mouse cell immunologic function, is shown in Table 5,6：
Influence of the composition of the present invention energy strengthen immunity of table 5 to mouse delayed allergy (DTH)
* relatively there is significant difference with blank group
As shown in Table 5, the composition of the present invention energy strengthen immunity of orally administration mouse various dose 30 days, high dose
For group swelling degree of the paw apparently higher than control group, difference has conspicuousness (P ＞ 0.05).
The influence that the composition of the present invention energy strengthen immunity of table 6 is tested to mouse lymphocyte conversion capability
* relatively have with blank group significantly
It is middle and high from table 6, the composition of the present invention energy strengthen immunity of orally administration mouse various dose 30 days
Dosage group mouse lymphocyte conversion capability is compared with control group, variant conspicuousness (P ＞ 0.05).I.e. the present invention is middle and high
Dosage group can improve the mouse lymphocyte conversion capability of ConA inductions.
(4) influence of the health-care edible capsule of present invention energy strengthen immunity to humoral immunity, is shown in Table 7,8：
Influence of the composition of the present invention energy strengthen immunity of table 7 to mouse antibodies cellulation number
* relatively have with blank group notable (P ＜ 0.05)；* relatively has extremely significantly (P ＜ 0.01) with blank group
As shown in Table 7, the composition of the present invention energy strengthen immunity of orally administration mouse various dose 30 days, it is middle and high
For dosage group mouse antibodies cellulation number apparently higher than control group, difference has conspicuousness (P ＜ 0.05 or P ＜ 0.01).I.e. originally
Invention capsule can improve mouse antibodies cellulation number in high dose.
The composition of the present invention energy strengthen immunity of table 8 is to mouse half hemolytic value (HC50) influence
* relatively has notable (P ＜ 0.01) with blank group
From table 8, the composition of the present invention energy strengthen immunity of orally administration mouse various dose 30 days, high dose
For group mouse half hemolytic value compared with according to group, difference has conspicuousness (P ＜ 0.01).I.e. the present invention can improve mouse in high dose
Half hemolytic value.
(5) present invention can strengthen immunity influence of the composition to mouse monokaryon-macrophage phagocytic function, be shown in Table 9,
10、11：
Shadow of the health-care edible capsule of the present invention energy strengthen immunity of table 9 to the macrophage carbonic clearance ability of mouse monokaryon one
Ring
* relatively have with blank group notable (P ＜ 0.05)
From table 9, the composition of the present invention energy strengthen immunity of orally administration mouse various dose 30 days, high dose
Group mouse phagocytic index is significantly higher than control group, and difference has conspicuousness (P ＜ 0.05).I.e. the present invention can improve small in high dose
Mouse carbonic clearance ability.
The composition of the present invention energy strengthen immunity of table 10 swallows the influence of chicken red blood cell phagocytic rate to mouse macrophage
The composition of the present invention energy strengthen immunity of table 11 swallows the shadow of chicken red blood cell phagocytic index to mouse macrophage
Ring
From table 10-11, the composition of the energy strengthen immunity of the invention of orally administration mouse various dose 30 days, respectively
Dosage group is compared with blank group, and there was no significant difference (P ＞ 0.05).I.e. each dosage group swallows chicken red blood cell to mouse macrophage
Ability has no significant effect.
(6) influence of the composition of present invention energy strengthen immunity to NK cells in mice activity, is shown in Table 12：
Influence of the composition of the present invention energy strengthen immunity of table 12 to NK cells in mice activity
From table 12, the composition 30 days, each dose of the present invention energy strengthen immunity of orally administration mouse various dose
Amount group is active to NK cells in mice compared with control group, no significant difference (P ＞ 0.05).I.e. to NK cells in mice activity without bright
Development rings.
5. experiment conclusion
In this experiment, orally administration mouse low dosage, middle dosage, the composition of the present invention energy strengthen immunity of high dose
30 days, high dose can strengthen mouse delayed allergy, improve the antibody-producting cell number of mouse, raising mouse monokaryon-huge
The ability of phagocyte carbonic clearance, high dose can improve mice serum half hemolytic value, the mouse lymphocyte conversion of ConA inductions
Ability.Compared with control group, P ＜ 0.05 or P ＜ 0.01.To mouse weight growth, spleen/body weight ratio, thymus gland/weight ratio
Value, NK cells in mice activity, the ability of mouse macrophage chicken red blood cell have no significant effect.Middle dose group induces ConA small
Mouse lymphotactin conversion capability, the antibody-producting cell number of mouse is improved, with control group than P ＜ 0.05, had a significant impact, with
The health food of upper experimental result prompting present invention energy strengthen immunity has the function of strengthen immunity.
In this experiment, 2.1 lower A1-A4 groups are to mouse delayed allergy, the antibody-producting cell of raising mouse
Number, the ability of monocytes/macrophages carbonic clearance, half hemolytic dose, ConA induction mouse lymphocyte conversion capability without
Remarkable effect, but compared with blank group, have the effect of improving.To mouse weight growth, spleen/body weight ratio, thymus gland/
Body weight ratio, NK cells in mice activity, the ability of mouse macrophage chicken red blood cell have no significant effect.
Comparative example 1
Except not adding saline cistanche in component, other conditions are the same as embodiment 1.
Comparative example 2
Except not adding jujube in component, other conditions are the same as embodiment 1.
Comparative example 3
Except not adding American Ginseng in component, other conditions are the same as embodiment 1.
Comparative example 4
Saline cistanche is comprised only in component, other conditions are the same as embodiment 1.
Comparative example 5
Jujube is comprised only in component, other conditions are the same as embodiment 1.
Comparative example 6
American Ginseng is comprised only in component, other conditions are the same as embodiment 1.
Claims (6)
1. the health composition containing saline cistanche of a kind of strengthen immunity, it is characterised in that said composition is matched by following weight
Raw material is made：Saline cistanche：2~4 parts；American Ginseng：1~3 part；Jujube：16~24 parts.
2. the health composition containing saline cistanche of the strengthen immunity described in claim 1 is preparing alleviation or is improving gas the moon two
Application in void, kidney-yang deficiency, deficiency in both YIN and YANG and weakly health food.
3. application according to claim 2, described health food is beverage or powdery or granular nutrient powder or done
Property food.
4. a kind of preparation method of the health composition containing saline cistanche of the strengthen immunity described in claim 1, its feature exist
Carried out as steps described below in this method：
Saline cistanche, American Ginseng, jujube are added water to cook 1-2 times, and every time plus 7-25 times is measured decocting and boil 1-3 hours；After extraction terminates, receive
Collect all filtrates, let cool, centrifuge, take supernatant, concentrate and produce.
A kind of 5. health drink containing saline cistanche of strengthen immunity, it is characterised in that the raw material that the beverage is matched by following weight
It is made：Saline cistanche：2~4 parts；American Ginseng：1~3 part；Jujube：16~24 parts, milk powder：20~40 parts.
6. the preparation method of the health drink containing saline cistanche of strengthen immunity according to claim 5, it is characterised in that
This method comprises the steps：
1) pretreatments of raw material：Saline cistanche, American Ginseng, jujube cleaning, 30-50 DEG C of low temperature drying are taken respectively, using preceding respectively by meat
Desert cistanche, American Ginseng carry out cutting, cutting flakiness or fritter；
2) is extracted：Saline cistanche, American Ginseng, jujube are added water to cook 1-2 times, and every time plus 7-25 times is measured decocting and boil 1-3 hours；
3) is centrifuged：After extraction terminates, all filtrates are collected, room temperature lets cool, centrifuged, and takes supernatant；
4) matches somebody with somebody liquid：Add milk powder and beverage is made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610785669.5A CN107788529A (en) | 2016-08-31 | 2016-08-31 | A kind of health composition of strengthen immunity containing saline cistanche and its beverage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610785669.5A CN107788529A (en) | 2016-08-31 | 2016-08-31 | A kind of health composition of strengthen immunity containing saline cistanche and its beverage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107788529A true CN107788529A (en) | 2018-03-13 |
Family
ID=61529343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610785669.5A Pending CN107788529A (en) | 2016-08-31 | 2016-08-31 | A kind of health composition of strengthen immunity containing saline cistanche and its beverage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107788529A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1951434A (en) * | 2006-09-29 | 2007-04-25 | 李志民 | Soft capsule with broomrape and Chinese date having fatigue-resisting radiation-resisting function and preparation method thereof |
| CN101822746A (en) * | 2009-03-04 | 2010-09-08 | 北京因科瑞斯医药科技有限公司 | Chinese medicinal composition with function of enhancing immunity and preparation method thereof |
| CN101850052A (en) * | 2009-03-31 | 2010-10-06 | 北京因科瑞斯医药科技有限公司 | Immunity-enhancing pharmaceutical composition and preparation method thereof |
| CN102488064A (en) * | 2011-12-28 | 2012-06-13 | 贵州神奇集团控股有限公司 | Health-preserving jujubes containing cistanche deserticola, and preparation method thereof |
-
2016
- 2016-08-31 CN CN201610785669.5A patent/CN107788529A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1951434A (en) * | 2006-09-29 | 2007-04-25 | 李志民 | Soft capsule with broomrape and Chinese date having fatigue-resisting radiation-resisting function and preparation method thereof |
| CN101822746A (en) * | 2009-03-04 | 2010-09-08 | 北京因科瑞斯医药科技有限公司 | Chinese medicinal composition with function of enhancing immunity and preparation method thereof |
| CN101850052A (en) * | 2009-03-31 | 2010-10-06 | 北京因科瑞斯医药科技有限公司 | Immunity-enhancing pharmaceutical composition and preparation method thereof |
| CN102488064A (en) * | 2011-12-28 | 2012-06-13 | 贵州神奇集团控股有限公司 | Health-preserving jujubes containing cistanche deserticola, and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 董广民: "《本草纲目 食物药物养生全书》", 31 May 2015 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107772433A (en) | One kind, which has, alleviates physical fatigue, strengthen immunity composition and preparation method thereof | |
| CN102526477B (en) | Medicine composition for enhancing immunities as well as preparation method and application thereof | |
| CN102242044A (en) | Cordyceps cicadae wine and preparation method thereof | |
| CN104667197B (en) | A kind of composition of strengthen immunity and its preparation method and application | |
| CN103585400B (en) | Have and strengthen immunologic function and the compositions alleviating fatigue effect and preparation method thereof | |
| CN102634441A (en) | Method for preparing health-care vinegar | |
| CN101810657B (en) | American ginseng contained composition and American ginseng tea drink | |
| CN101461918B (en) | Medicament composition for treating male climacteric syndrome and delaying age | |
| CN102318865B (en) | Functional beverage and preparation method | |
| CN105106434A (en) | Wolfberry fruit and American ginseng soft capsules and preparation method thereof | |
| CN107802695A (en) | A kind of health composition of the strengthen immunity containing saline cistanche and preparation method thereof | |
| CN107568740A (en) | A kind of health-care food composition, its preparation method and the purposes in terms of strengthen immunity | |
| CN106923334A (en) | A kind of astaxanthin flexible glue capsule formula and preparation method thereof | |
| CN101779791B (en) | Composition with health care functions and preparation method thereof | |
| CN103690573B (en) | A kind of natural drug composition for strengthen immunity and preparation method thereof | |
| CN102283883B (en) | Health-care oral liquid for enhancing immunity and relieving physical fatigue and preparation method thereof | |
| CN107788529A (en) | A kind of health composition of strengthen immunity containing saline cistanche and its beverage | |
| CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
| CN1252241C (en) | Health wine for strengthening immunity and its preparing method | |
| CN106728962B (en) | Pharmaceutical composition for enhancing immunity and application thereof | |
| CN102475201A (en) | Protein powder composition with health care function | |
| CN102406172B (en) | Health-care food for enhancing immunity and preparation method thereof | |
| CN104042790B (en) | A kind of pharmaceutical composition and its application for health care for the middle and old aged | |
| CN105815786A (en) | Tablets prepared from honeysuckle flowers, wild chrysanthemum flowers and rhizoma polygonati and preparation method of tablets | |
| CN105455122A (en) | Spirulina tablet and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180313 |
|
| RJ01 | Rejection of invention patent application after publication |